The Financial Express6d
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Fierce Pharma5d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
MedPage Today on MSN21h
Endocrine Society's New President-Elect; Judge Stops Compounders; New GLP-1 Benefits
Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...
Pfizer appoints former J&J executive to lead obesity drug development
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
pharmaphorum1d
Novo Nordisk launches recycling programme for pen injectors
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... and an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, long ...